New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory

This publication has 67 references indexed in Scilit:

• Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam
  Drug Testing and Analysis, 2021
• Designer Benzodiazepines: A Review of Published Data and Public Health Significance
  Clinical Pharmacology in Drug Development, 2019
• Designer Benzodiazepines: Another Class of New Psychoactive Substances
  2018
• Application of a screening method for fentanyl and its analogues using UHPLC‐QTOF‐MS with data‐independent acquisition (DIA) in MS^E mode and retrospective analysis of authentic forensic blood samples
  Drug Testing and Analysis, 2017
• The emergence of new psychoactive substance (NPS) benzodiazepines: A review
  Drug Testing and Analysis, 2017
• Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography–high resolution mass spectrometry
  Drug Testing and Analysis, 2017
• Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
  Drug Testing and Analysis, 2016
• Novel psychoactive substances of interest for psychiatry
  World Psychiatry, 2015
• Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology
  Drug Testing and Analysis, 2014
• Cross‐reactivity of designer drugs, including cathinone derivatives, in commercial enzyme‐linked immunosorbent assays
  Drug Testing and Analysis, 2013